First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastati…

Blue Earth Therapeutics today announced that the first patients in the UK have been administered with the investigational ...

Blue Earth Therapeutics Limited: First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programmeThe patients received Lutetium (177Lu) rhPSMA-10.1 Injections at ...
TMCnet

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance ...
The Manila Times

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...
Science Daily

Study solves testosterone's paradoxical effects in prostate cancer

A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay disease progression in ...